RO 256981

Drug Profile

RO 256981

Alternative Names: RO 25-6981

Latest Information Update: 04 Dec 2008

Price : $50

At a glance

  • Originator Roche
  • Class Antiparkinsonians; Neuroprotectants; Small molecules
  • Mechanism of Action NR2B N-Methyl-D-Aspartate antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Neurological disorders

Most Recent Events

  • 15 Feb 2006 No development reported - Preclinical for Neurological disorders (Prevention) in Switzerland (unspecified route)
  • 01 Sep 2003 This compound is still in active development
  • 26 Jun 2001 No-Development-Reported for Neurological disorders (Prevention) in Switzerland (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top